31 results about "Drug encapsulation" patented technology

This invention discloses a polymer-loaded drug-eluting nanoparticle with high encapsulation efficiency and its application in coatings and surface film materials. The polymer-loaded drug-eluting nanoparticles are prepared via emulsion polymerization, simultaneously loading antibacterial drugs with different log P values. The preparation process is simple, and the resulting product has small particle size, high molecular weight, high uniformity, and high drug encapsulation efficiency, achieving the substitution of non-reactive surfactants with reactive surfactants. A coating can be prepared using the above-mentioned polymer-loaded drug-eluting nanoparticles. The coating can be further used to prepare sustained-release antibacterial surface film materials through cross-linking film formation, exhibiting good mechanical properties, excellent chemical resistance, and high safety. This invention can be widely applied to various environmental and material surfaces, including but not limited to surface modification of instruments and building materials in residential and medical environments, thereby achieving a long-lasting antibacterial effect.

The invention discloses a production process of lipid nanoparticles entrapped with weak-acid and weak-hydrophobicity small molecule drugs, which comprises the following steps: S1, preparing a water phase and an organic phase, the organic phase comprising a lipid organic phase and a drug organic phase; s2, under an ultrasonic condition, successively mixing the water phase, the drug organic phase and the lipid organic phase in a microreactor through a microfluidic technology to form lipid nanoparticles, so as to obtain a crude sample containing the lipid nanoparticles; s3, diluting the crude sample by using a PBS (Phosphate Buffer Solution), and standing to obtain a sample diluent; s4, the sample diluent is subjected to ultrafiltration concentration, a concentrated sample is obtained, and a lipid nanoparticle product loaded with the medicine components is obtained. By adjusting the mixing time of the lipid component phase and other two-phase solutions, the drug precipitation rate and the lipid component precipitation rate are flexibly regulated and controlled, the drug encapsulation efficiency is effectively improved, and industrial production is facilitated.

The present invention relates to a continuous ultrasonic reactor capable of performing continuous chemical reactions using multiple ultrasonic generators installed in parallel. The reactor body includes a reactant inlet and a product outlet, and the ultrasonic generators are uniformly arranged inside the reactor to induce mixing of reactants and the generation of free radicals through ultrasonic cavitation. As a result, the reaction can be effectively initiated without the use of a chemical initiator, and the reaction speed and efficiency are significantly improved. In addition, a cooling jacket is installed on the exterior of the reactor to stably maintain the reaction temperature, thereby ensuring uniformity of reaction conditions. The operating conditions of the ultrasonic generators can be adjusted via a control panel, allowing for flexible application to various chemical reaction processes. The present invention can be utilized in high-efficiency chemical processes such as polymer polymerization, nanoparticle synthesis, and drug encapsulation, and is an innovative technology that simultaneously provides energy efficiency and eco-friendliness.

This invention discloses a method for preparing avermectin nanoparticles supported on zein-sodium lignin sulfonate, and its applications. The preparation method involves dissolving avermectin and zein in an organic solvent to form a solution (stream 1), and dissolving sodium lignin sulfonate or modified sodium lignin sulfonate in deionized water to form a solution (stream 2). Both streams are simultaneously injected into a dual-channel confined counter-current mixer for rapid mixing. The resulting nanoparticle suspension is then collected, completing the preparation process. This invention utilizes the compatibility of hydrophobic zein with avermectin, combined with the self-assembly properties of zein and the use of sodium lignin sulfonate or modified sodium lignin sulfonate as a stabilizer, to prepare avermectin nanoparticles with high drug encapsulation efficiency and excellent drug release performance. Furthermore, these nanoparticles exhibit excellent resistance to UV photodegradation, effectively reducing the photodegradation of avermectin. The method is simple, rapid, and easy to control.

The invention discloses papaverine hydrochloride sustained-release microspheres for injection and a preparation method of the papaverine hydrochloride sustained-release microspheres, and relates to the technical field of pharmaceutical preparations. The sustained-release microsphere comprises an active component, a composite carrier, a composite stabilizer and a freeze-drying protective agent. The composite carrier is a compound formed by grafting a polylactic acid-glycolic acid copolymer and hyaluronic acid, the composite stabilizer is a mixture of an antioxidant and an amino acid compound, the freeze-drying protective agent is a mixture of polyol and saccharides, and the surface of the microsphere is provided with a hydrophilic-hydrophobic gradient coating composed of a hydrophobic layer, an amphiphilic layer and a hydrophilic layer. The preparation method comprises the steps of primary emulsion preparation, multiple emulsion preparation, step-by-step curing, surface modification and freeze-drying treatment, and adopts the processes of gradient emulsification, step-by-step curing, layer-by-layer grafting, gradient cooling and segmented sublimation. According to the technical scheme, the drug encapsulation efficiency and the drug loading capacity are effectively improved, the burst release rate is reduced, long-acting stable slow release is realized, the storage stability and the biocompatibility are enhanced, and a safe and effective drug administration choice is provided for treatment of ischemic diseases.

The invention discloses lipidosome, a medicine lipidosome compound and a preparation method and application of the medicine lipidosome compound. The liposome comprises the following components in parts by mass: 10-65 parts of saturated phospholipid; 25 to 75 parts of unsaturated phospholipid; 0.5 to 15 parts of a trigger lipid; the trigger lipid is sphingolipid and / or cholesterol; the mass ratio of the saturated phospholipid to the unsaturated phospholipid is (0.20-2.50): 1. When the lipidosome is used for drug encapsulation, high encapsulation efficiency can be guaranteed, high activity of drugs can be maintained, the lipidosome can be stably stored, and a universal carrier is provided for drugs with different physicochemical properties (especially highly hydrophilic drugs, such as protein drugs and nucleic acid drugs).

The invention discloses a deep learning-based lamp inspection data monitoring system after drug encapsulation and sterilization, and the system comprises the steps: carrying out the cumulative calculation of a determined intensity change sequence through a dose integration algorithm, fusing the position coordinates and the stay time information, and obtaining the actual accepted dose value of each drug; if the obtained actual accepted dose value is lower than the preset sterilization threshold value, triggering an environment factor adjustment module to simulate the three-dimensional attenuation atlas again, and judging whether the adjusted three-dimensional attenuation atlas improves the coverage rate of a low-intensity area or not; obtaining optimized intensity distribution data by comparing the difference between the adjusted three-dimensional attenuation atlas and the original atlas, and determining the expected dose increase amplitude under the drug re-path; updating input parameters of a dose integration algorithm according to the determined lifting amplitude, and recalculating dose values of all the medicines to obtain an overall sterilization consistency index of the batch; if yes, outputting a personalized evaluation report, and judging that the sterilization state of each medicine meets the requirement.

The invention relates to the technical field of protein drugs, in particular to a human ferritin light chain variant and a glycosylation modified human ferritin light chain variant. According to the invention, an N-glycan modification sequence is introduced at a proper position, and the obtained human ferritin light chain variant can be used for constructing a glycosylation modified human ferritin light chain. The glycosylation-modified human ferritin light chain has good stability and protease degradation resistance, the immunogenicity is remarkably reduced, and meanwhile, a natural cavity structure is reserved, so that the glycosylation-modified human ferritin light chain can be used as a drug carrier to realize good embedding of drugs.

The invention relates to an anti-inflammatory and lipid-lowering-based nano preparation for treating fatty liver and a preparation method of the nano preparation. Galactose modified polyethylene glycol-polylactic acid-glycolic acid copolymer (PEG-PLGA) is used as a targeting carrier, and a lipid-lowering drug fenofibrate and an anti-inflammatory drug curcumin are co-loaded; the particle size of the nano preparation is 150-200nm, and the drug encapsulation efficiency is greater than or equal to 85%. Galactose modified PEG-PLGA is adopted as a carrier, galactose can be specifically combined with an asialoglycoprotein receptor (ASGPR) specifically expressed on the surface of liver cells, active targeting of the liver is achieved, the drug enrichment amount of the liver lesion position is remarkably increased, meanwhile, accumulation of drugs in extrahepatic tissue is reduced, extrahepatic toxicity is effectively reduced, and the drug delivery effect is improved. According to the present invention, the anti-inflammatory drug curcumin and the fenofibrate are combined, such that the biological safety of the preparation is improved, the lipid lowering drug fenofibrate and the anti-inflammatory drug curcumin are innovatively co-loaded, and the fenofibrate and the anti-inflammatory drug curcumin form the synergistic effect system: fenofibrate can activate peroxisome proliferator-activated receptor alpha (PPAR alpha), promote liver lipid catabolism, and reduce lipid deposition;

A liposome of a nitrogen-containing heterocyclic compound comprises the following components: a nitrogen-containing heterocyclic compound as shown in compound 3 below and a lipid component. The liposomes of the present invention satisfy one or more of the following advantages: (1) small particle size and uniform distribution; (2) high API content; (3) high drug encapsulation efficiency; (4) good stability; (5) good antitumor activity; (6) good safety; and (7) long-lasting effect.

The invention relates to the technical field of pharmaceutical preparations, and discloses a doxorubicin and cyclophosphamide liposome compound injection which is prepared from doxorubicin hydrochloride, cyclophosphamide, hydrogenated soybean phosphatidylcholine, cholesterol, polyethylene glycol derivative phospholipid, anhydrous magnesium sulfate, L-arginine and a sucrose octasulfate ammonium solution. Magnesium ions introduced into an inner water phase participate in competitive binding, doxorubicin and sucrose octasulfate are induced to form a loose co-precipitation structure with lattice defects, hydrophilic cyclophosphamide is physically filled and cured by using micro gaps, and efficient encapsulation of non-gradient dependent drugs is realized. Meanwhile, an in-situ pH buffer system is constructed by using L-arginine, protons generated in a drug loading process are neutralized, an internal water phase is maintained in a neutral environment, and acid-catalyzed hydrolysis of cyclophosphamide is effectively inhibited. According to the invention, the double-drug encapsulation efficiency and storage stability of the compound liposome are obviously improved.

This invention relates to a method for preparing resveratrol nanoparticles, belonging to the field of traditional Chinese medicine technology. Addressing the problems of low oral bioavailability and lack of colonic targeting of resveratrol, this invention provides a nanoparticle formulation composed of resveratrol, zein, and xylan. The formulation is prepared by dissolving resveratrol and zein in an organic phase, adding them dropwise to an aqueous xylan phase, and then evaporating the organic solvent. This invention utilizes the hydrophobic effect of zein to improve drug encapsulation efficiency and leverages the colonic degradation characteristics and anti-inflammatory activity of xylan to achieve synergistic effects, enabling precise release of resveratrol at sites of intestinal inflammation.

The application discloses a pre-gelatinized starch / calcium-containing mineral-berberine compound and a preparation method and application thereof, and comprises the following steps: mixing an organic acid salt or an inorganic acid salt, starch and water, and performing microwave treatment to obtain a starch-salt colloid solution; mixing calcium salt, berberine and ethanol to obtain an ethanol solution containing berberine and calcium salt; adding the starch-salt colloid solution into the ethanol solution containing berberine and calcium salt, stirring and reacting, performing retrogradation treatment, centrifuging to obtain a precipitate, and drying to obtain the compound. The application combines the starch "gelatinization-retrogradation" mechanism and the calcium-containing mineral biomimetic mineralization method, completes the encapsulation of berberine, and prepares the berberine compound with the pre-gelatinized starch / calcium-containing mineral as a drug delivery system, so that the berberine compound has a high drug encapsulation rate, the gastrointestinal stability of the berberine is remarkably improved, a good sustained-release effect is generated, the bioavailability of the berberine is improved, and a new way is provided for the clinical application of the berberine.

The invention discloses a preparation method of a gamma-PGA nanofiber membrane for skin repair, and relates to the technical field of nanofiber membranes, and the preparation method comprises the following steps: (1) preparing a gamma-PGA spinning solution and a drug spinning solution, and respectively filling the gamma-PGA spinning solution and the drug spinning solution into an outer cylinder and an inner cylinder which are coaxially arranged; (2) setting parameters such as the spinning voltage of 20-25kV, the distance between a needle head and a receiving disc of 16-19cm and the like; (3) a positioning cover is used for preventing wind, a shockproof mechanism is used for damping, and fiber membranes with the thickness of 50-200 microns are synchronously spun and collected; and (4) performing vacuum drying to obtain the product. A device used in the method comprises a positioning cover, double coaxial cylinders, a shockproof mechanism and the like, the thickness uniformity error of the fiber membrane is smaller than or equal to 5%, the drug encapsulation efficiency is larger than or equal to 85%, and the skin wound healing rate within 7 days is larger than or equal to 85%. The defect that the form is affected by jet flow deviation and vibration in the prior art is overcome, the synergistic function of base material supporting and medicine slow release is achieved, and the device is suitable for scenes such as skin wound repair and medical and art post-care.

The invention discloses preparation and application of a nucleotide and nucleotide derivative bridged lipid nucleic acid delivery system, and belongs to the technical field of biological medicine. The nucleotide and nucleotide derivative bridged lipid nucleic acid delivery system is composed of lipid nanoparticles, a nucleic acid drug and nucleotide / nucleoside / base / ribose / deoxyribose, exogenous nucleotide components are tightly combined with the nucleic acid drug through hydrogen-bond interaction and base stacking force, the stability and translation efficiency of mRNA are enhanced, and the delivery effect of the nucleotide and nucleotide derivative bridged lipid nucleic acid delivery system is improved. And then loading the two into the lipid nano-particles through electrostatic interaction. The delivery system has significant advantages in improving the entrapment efficiency, stability, transfection efficiency and cell survival rate of nucleic acid drugs, can be delivered through intravenous administration, intramuscular injection, aerosol inhalation and the like, can significantly improve the disease treatment efficiency, and has wide clinical application prospects.

The invention discloses a ginsenoside glutathione liposome as well as a preparation method and application thereof, and particularly provides the ginsenoside glutathione liposome which is characterized in that raw materials of the ginsenoside glutathione liposome comprise the following components in percentage by mass: 15%-20% of glutathione, 5%-10% of ginsenoside, 35%-40% of sunflower lecithin and 35%-40% of maltodextrin. The mass fraction refers to the mass percentage of each component in the raw materials. The ginsenoside glutathione liposome provided by the invention is stable in property, controllable in particle size, high in drug encapsulation efficiency, good in drug stability, high in bioavailability and gastrointestinal absorption rate and reasonable in compatibility; the preparation process is relatively good, the preparation conditions are easy to realize, and industrialization is facilitated; the optimization of the combination of the preparation process and the product performance is realized.

The invention provides a nanoparticle based on an amphiphilic polymer and application thereof, the nanoparticle comprises the amphiphilic polymer, a chemotherapy drug and an immunotherapy drug, and the amphiphilic polymer contains a tumor microenvironment response group, an aggregation-induced emission group and a hydrophilic cation group. The nanoparticles wrap chemotherapy drugs through hydrophilic and hydrophobic effects of polymers, wrap negative charge immunotherapy drugs through electrostatic interaction, and have efficient responsiveness to tumor microenvironments, aggregation-induced emission characteristics and excellent drug wrapping capacity, so that the synergistic treatment effect of chemotherapy, immunotherapy and photodynamic therapy is achieved, and the application prospect is broad. The anti-tumor curative effect of the medicine is obviously improved.

The invention relates to lipid nanoparticles for co-delivery of platinum derivatives and small nucleic acids as well as a preparation method and application of the lipid nanoparticles, and belongs to the technical field of biological medicines. The lipid nanoparticle comprises a lipid bilayer and small nucleic acid entrapped by the lipid bilayer, wherein the lipid bilayer comprises a cationic polymer, a pegylated platinum derivative, pegylated phospholipid, structural lipid and structural phospholipid; the small nucleic acid is siRNA, ASO or shRNA, and the small nucleic acid is combined with a hydrophilic head group of the lipid bilayer. According to the lipid nanoparticles prepared by the invention, two drugs are encapsulated in the same system, so that synchronous delivery of the two drugs can be realized; the lipid nanoparticles can protect small nucleic acids from being degraded in circulation, actively target tumor tissues and increase accumulation of drugs at tumor parts; the lipid nanoparticles can promote release of nucleic acid drug lysosome by utilizing tumor microenvironment characteristics, and have a good application prospect.

This invention discloses a mesoporous polydopamine nanoparticle loaded with tesipatide, its preparation method, and its application. The preparation method of the tesipatide-loaded mesoporous polydopamine nanoparticles of this invention includes the following steps: First, under solvent conditions, dopamine hydrochloride and a nonionic copolymer are mixed, then a hydrophobic pore-expanding agent and a catalyst are added sequentially, and the mixture is reacted to obtain mesoporous polydopamine nanoparticles; then, these nanoparticles are dispersed in an aqueous solvent, tesipatide is added, and after mixing and reaction, the tesipatide-loaded mesoporous polydopamine nanoparticles are obtained. The tesipatide-loaded mesoporous polydopamine nanoparticles prepared by the method of this invention not only have excellent drug encapsulation efficiency and sustained drug release effect, but also, when used to treat obesity, can effectively reduce patients' weight and random blood glucose, and significantly improve patients' glucose tolerance, insulin sensitivity, and energy expenditure rate.

This invention discloses a ginsenoside-modified ceramide liposome, its preparation method, and its application, belonging to the field of cosmetic preparation technology. The liposome is composed of ceramide, phosphatidylcholine, ginsenoside Rg3, and water. Addressing the shortcomings of existing ceramide liposomes, such as poor physical stability and low transdermal absorption, this invention innovatively utilizes the unique amphiphilic molecular structure of ginsenoside Rg3, embedding it as a functional modifier into the liposome bilayer. The hydrophobic steroidal backbone of Rg3 is tightly bound to the lipid tail through hydrophobic interactions, with the hydrophilic sugar chains facing the aqueous phase. This not only acts as a "molecular anchor," significantly enhancing the density of the lipid bilayer and improving the physical stability and drug encapsulation efficiency of the liposome, but also endows the liposome with excellent antioxidant, anti-inflammatory, and skin microcirculation-promoting bioactivity. The liposomes prepared by this invention achieve deep transdermal delivery and long-lasting release of ceramides, effectively repairing damaged skin barriers; and utilize the bioactivity of Rg3 to achieve multiple effects of moisturizing, anti-aging, and repair. The preparation method of this invention is simple, mild, and reproducible. The resulting product can be widely used in the preparation of various skin care products such as creams, lotions, and serums, and has significant market application prospects.

The application belongs to the technical field of preparations for medical, dental or cosmetic use, and specifically discloses a self-assembled curcumin delivery system based on trityl nonaethylene glycol / ovalbumin, which is obtained by self-assembly of trityl nonaethylene glycol, ovalbumin and curcumin; and simultaneously discloses a preparation method of the curcumin delivery system. The drug delivery system prepared by the method significantly improves the drug encapsulation dispersion and cell absorption efficiency, and can be widely used in the fields of food, daily chemicals and medicines.

To provide an optimized amphiphilic carbohydrate compound for encapsulating a hydrophobic drug based on the study on the effect of acetylation on the self-assembly of an amphiphilic chitosan derivative and the encapsulation of the drug.SOLUTION: The present invention relates to acetylated amphiphilic carbohydrates compounds with average molecular weights from 1 to 50kDa based on glycol chitosans, wherein the level of acetylation can be varied. The compound can be formulated with a hydrophobic compound, such as a drug. The degree of acetylation of the carbohydrate compound is optimized to maximize solubilization of the drug. The compounds are formulated with drugs and are useful in therapy.SELECTED DRAWING: Figure 1

The invention relates to an astaxanthin and nicotinamide adenine dinucleotide co-loaded nano-drug and a preparation method and application thereof.The astaxanthin and nicotinamide adenine dinucleotide co-loaded nano-drug is prepared by taking hollow mesoporous polydopamine nano-particles as a carrier, sequentially loading ASX and NAD + and performing polyethylene glycol long-chain modification and drug encapsulation on the surfaces of the nano-particles, so that the astaxanthin and nicotinamide adenine dinucleotide co-loaded nano-drug is obtained. Therefore, the water-soluble nano-particles have better water solubility and stability. The co-loaded nano-drug is used for radiation protection, is used for preventing or relieving ionizing radiation injury, and has a remarkable treatment effect on radiation-induced lung injury after atomized targeted lung administration.

This invention discloses a method for preparing and studying the drug-loading properties of PEGMA-g-PEGMA-b-PCL polymer micelles, belonging to the field of drug carrier technology. The method first synthesizes a triblock graft copolymer using the ATRP method, then completes micelle self-assembly through solution dropwise addition, rotary evaporation, and membrane filtration. Using a hydrophobic antitumor drug as a model, drug-loaded micelles are prepared, and drug loading, release, stability, and cytotoxicity are simultaneously tested. This invention designs a hydrophilic grafted PEGMA-g-PEGMA structure and optimizes the preparation process parameters. The resulting micelles have a spherical core-shell structure with a particle size of 80-180 nm, exhibiting good self-assembly stability and pH response characteristics. The drug loading is ≥8.5%, the encapsulation efficiency is ≥80%, drug release is slow under physiological conditions, and the cumulative drug release rate in the tumor microenvironment is 75%-90% after 72 hours. Furthermore, it exhibits good storage stability and excellent biocompatibility, enabling efficient drug encapsulation and tumor microenvironment-responsive release. This method has significant application value in the preparation of targeted therapeutic carriers for hydrophobic antitumor drugs.

The application relates to the technical field of high polymer composite materials, and provides a composite microsphere, which comprises a core body and a coating layer covering the core body, the core body comprises doped hydroxyapatite doped with zinc ions and cerium ions, the coating layer comprises polylactic acid and beta-cyclodextrin, and graphene oxide is distributed between the core body and the coating layer; the composite microsphere has a porous structure, and beta-cyclodextrin is filled in at least part of the porous structure. The composite microsphere provided by the application can significantly improve the drug encapsulation performance of the composite microsphere by utilizing the synergistic effect among the Ce / Zn co-doped doped hydroxyapatite, polylactic acid, graphene oxide and beta-cyclodextrin, can effectively inhibit and reduce the initial burst release phenomenon of the drug, and can construct a stable, long-acting and controllable drug sustained-release system.

The invention provides an antibacterial electrostatic spinning fiber membrane, an antibacterial tourniquet and a preparation method, and relates to the technical field of medical materials. The antibacterial electrostatic spinning fiber membrane provided by the invention comprises a polylactic acid electrostatic spinning fiber membrane and broadleaf holly leaf carbon dots loaded in fibers of the polylactic acid electrostatic spinning fiber membrane, and the fibers are bead-like nanofibers. The polylactic acid is used as a material of the bead-like nanofiber, and meanwhile, the broadleaf holly leaf carbon dots with biocompatibility are added, so that the biocompatibility of the fiber is improved; the electrostatic spinning fiber membrane is composed of bead-like nanofibers with uniform forms, so that the permeability of the fibers is improved, and the electrostatic spinning fiber membrane has high drug encapsulation efficiency; the antibacterial electrostatic spinning fiber membrane entraps broadleaf holly leaf carbon dots with an antibacterial effect, and can resist bacteria for a long time. The invention provides an antibacterial tourniquet which can effectively reduce infection caused in the use process of the tourniquet and improve the cell compatibility of the existing tourniquet made of a high polymer material.

The invention discloses a drug encapsulation production monitoring device and a use method, and relates to the technical field of biological medicines.The drug encapsulation production monitoring device comprises a waste liquid collecting part, a sample collecting part and a monitoring assembly, and output pipelines capable of switching the conduction states are arranged between the monitoring assembly and the waste liquid collecting part and between the monitoring assembly and the sample collecting part correspondingly; the monitoring assembly is used for receiving a target medicine and detecting the component proportion of the target medicine; and the monitoring assembly is used for switching the conduction state of the two output pipelines according to the detection result of the component proportion of the target drug, can adapt to a traditional large-scale drug encapsulation production line, can be more flexibly embedded into a micro-fluidic chip and other miniaturized and integrated preparation scenes, ensures timely shunting of unqualified products, and effectively guarantees the quality and yield of final products.

The invention discloses a tumor-targeted metal organic framework nano-drug delivery system as well as a preparation method and application thereof, and belongs to the technical field of biological medicines. According to the invention, drugs are encapsulated in double-layer metal organic framework nanoparticles with a core-shell structure; the bacterial outer membrane vesicles are modified on the surfaces of the nanoparticles to form a nano-drug delivery system; the core layer material of the double-layer metal organic framework nanoparticles is MOF801, and the shell layer material of the double-layer metal organic framework nanoparticles is MOF199. The nano-drug delivery system can actively target a tumor site after being injected in a mouse tumor model through caudal vein, the double-layer metal organic framework structure is degraded under the co-stimulation of ATP and H < + > in a tumor microenvironment, and drugs are released to kill tumor cells. Meanwhile, Cu < 2 + > released by degradation can also catalyze a Fenton-like reaction to generate hydroxyl radicals so as to further kill tumor cells.

According to the present invention, it is possible to provide a drug carrier having excellent bioavailability and improved drug encapsulation efficiency by preparing lipoprotein-mimicking solid lipid nanoparticles having a core-shell structure consisting of albumin-conjugated cholesterol, a fusogenic lipid, a cationic lipid, a triglyceride and a cholesteryl ester.

The invention relates to the technical field of biological medicines, and particularly discloses a nano-liposome antitumor drug and a preparation method thereof.The nano-liposome antitumor drug is prepared through inner core double-drug entrapment, net support constructed by shell chitin and outer layer BSA covalent protection in combination with paclitaxel, Vandetanib and VEGFC multi-drug synergism, and the nano-liposome antitumor drug is prepared. The whole link characteristics of tumor cell killing, angiogenesis inhibition and microenvironment regulation and control are covered, the toxic and side effects of drugs and tumor drug resistance can be greatly reduced through synergistic fusion, the effectiveness of anti-tumor treatment is improved, and the problems that traditional lipidosome is poor in stability and drugs are prone to leakage are solved; through the precise process of layering preparation, covalent binding and freeze drying, the situation that due to the fact that a traditional liposome is unstable in structure, a drug is released in advance or a carrier is agglomerated is avoided, meanwhile, it is ensured that the drug is efficiently enriched at a tumor site, and the stable and efficient anti-tumor performance is kept in the whole period of patient treatment.